Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin |
| Indication/Tumor Type | colorectal cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | colorectal cancer | sensitive | Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (BREAKWATER) that supported FDA approval, Braftovi (encorafenib) in combination with Erbitux (cetuximab) and mFOLFOX6 significantly improved objective response rate (60.9%, 67/110 vs 40.0%, 44/110, OR 2.443, p=0.0008) compared to standard of care in patients with metastatic colorectal cancer harboring BRAF V600E, with median duration of response of 13.9 vs 11.1 mo, and overall survival was not estimable vs 14.6 mo (HR 0.47) (PMID: 39863775; NCT04607421). | detail... 39863775 detail... detail... |
| BRAF V600E | colorectal cancer | sensitive | Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with the combination of Erbitux (cetuximab), Braftovi (encorafenib), and FOLFOX resulted in increased tumor growth inhibition and survival compared to Erbitux (cetuximab) plus Braftovi (encorafenib) or FOLFOX alone in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 37040395). | 37040395 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Full reference... | ||
| Braftovi (encorafenib) FDA Drug Label | Full reference... | |
| Erbitux (cetuximab) FDA Drug Label | Full reference... | |
| (37040395) | Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. | Full reference... |
| (39863775) | Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. | Full reference... |